DAIICHI-SANKYO
Daiichi Sankyo (TSE: 4568) today announced that it has opened a new affiliate for its oncology business in Athens, Greece. The establishment highlights the company’s strong commitment to addressing treatment needs of people living with cancer in the European region. Thomais Konstantopoulou has been appointed Country Manager, Daiichi Sankyo Greece Single Member S.A.
“We are very happy to open yet another new affiliate in Europe to bring our innovative medicines to patients who can benefit from them. To have representation in a country is the best way of doing this,” said Thomais Konstantopoulou, Country Manager, Daiichi Sankyo Greece. “Our decision to establish a presence in Greece stems from our deep-rooted commitment to serving as many patients with cancer as possible with our innovative portfolio, aiming to improve outcomes and quality of life. It also is linked to a continuous effort of multiple stakeholders that elevates oncology in the country’s healthcare agenda and promotes active dialogue. Daiichi Sankyo is investing in Greece, which aligns with the country’s ambition to create conditions that foster innovation, talent retention, technology advancement and economic growth. We are focused on advancing meaningful innovation and creating jobs in a sustainable manner.”
Daiichi Sankyo has affiliates in 14 European countries, alongside representations in Norway, Finland, Sweden and Luxembourg. Europe has always been a focus for the company’s medicines, as well as a key region for continuous investment. With 20 research and development sites across 12 countries, Daiichi Sankyo utilizes a global network to drive innovation. Currently, the company is focused on developing antibody drug conjugates (ADCs), which are targeted cancer medicines that combine target-specificity and anti-tumor activity in a single molecule.
“From pursuing new medicines and new methods of drug discovery and delivery to achieving excellence throughout our organization by continuously examining new ideas, innovation is paramount for all we do,” said Dr. Dimitrios Krikelis, Head of Medical Affairs, Daiichi Sankyo Greece. “Even before the establishment of the Greek affiliate, Daiichi Sankyo has been partnering with the local oncology community through our clinical development program. We are fortunate to have physicians with a wealth of clinical expertise and a vibrant research community in Greece.”
Daiichi Sankyo aims to be an active contributor to the Greek healthcare ecosystem by partnering with the scientific community, governmental organizations and patient advocacy groups in order to provide value to patients, healthcare professionals and health authorities.
About Daiichi Sankyo
Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular and other diseases with high unmet medical need. For more information, please visit www.daiichi-sankyo.eu.
HQ/ONP/07/24/0007
| _______________________________ |
1 https://www.jto.org/article/S1556-0864(20)31099-6/fulltext |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240709254444/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NIQ, World Data Lab, and SPATE launch "Beauty Futures" Report - A guide to generational journeys of global beauty buyers9.12.2024 15:00:00 CET | Press release
Comprehensive report reveals generational beauty spending trends and preferencesMillennials drive the highest growth at US$193 Billion overtaking Gen X by 2034Gen X lead beauty spending in 2024, with an expected $150B increase over the next decade NielsenIQ (NIQ) collaborated with World Data Lab and SPATE to release a comprehensive generational report purely focused on the beauty market in the next decade. The report reveals key insights into generational preferences, spending habits, values, priorities, motivators, shopping behaviors, and their influence on global beauty trends. It highlights the crucial role each generation will play in shaping consumer preferences and spending over the next decade. Millennials will be at the helm of this trend by driving nearly half of global beauty spend at US$ 193 Billion with Gen Z coming a close second at US$ 158 Billion. The global beauty industry is seeing unprecedented growth at US$ 1.1 Trillion, with a projected growth of US$ 700 Billion by
SLB adds AI-driven geosteering to its autonomous drilling solutions to achieve more efficient and productive wells9.12.2024 14:29:00 CET | Press release
Intelligent closed-loop drilling system dynamically responds to subsurface geological informationKeeps well trajectory in the “sweet spot” of the reservoir for maximum productionImproves efficiency — minimizing the carbon footprint of drilling operations Global energy technology company SLB (NYSE: SLB) introduces Neuro™ autonomous geosteering, which dynamically responds to subsurface complexities to drill more efficient, higher-performing wells, while reducing the carbon footprint of the drilling operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241127402342/en/ Using AI, Neuro geosteering integrates and interprets complex real-time subsurface information to autonomously guide the drill bit through the most productive layer or “sweet spot” of the reservoir. (Photo: Business Wire) Using artificial intelligence (AI), Neuro geosteering integrates and interprets complex real-time subsurface information to autonomously g
DeepGreenX Group and Hues Capital Launch $10 Billion USD Fund to Accelerate AI, Green Energy, and Computing Power9.12.2024 13:00:00 CET | Press release
New DXG-Hues Fund will target innovative enterprises and solutions in these transformative ecosystems worldwide DeepGreenX Group Inc. (“DeepGreenX,” “DXG,” or the “Company”), an AI-enabled green energy and technology company, and Hues Capital (“Hues”), a leading capital provider enabling financial technology ecosystems, AI, and green energy enterprises, jointly announced the formation of a new $10 billion USD fund (the “Fund”) to drive global advancements in AI, green energy, and computing power and accelerate sustainability initiatives worldwide. DeepGreenX and Hues will each hold a 50% stake and act as co-general partners in the $10 billion USD DXG-Hues parent fund, which will be based in the EU and comprise two $5 billion USD sub-funds: the DXG-Hues AI Computing Infrastructure Fund and the DXG-Hues AI Energy Fund. The former will focus on global investments in AI computing power and green energy infrastructure projects, while the latter will target emerging enterprises in the fields
Kinaxis Offers a Solution to Streamline Bel’s Supply Chain9.12.2024 13:00:00 CET | Press release
Bel Group, a major player in food through dairy, fruit and plant-based healthier eating portions, with iconic international brands such as The Laughing Cow®, Kiri®, Babybel®, Boursin®, Nurishh®, or GoGo squeeZ®, has partnered with Kinaxis® Inc. (TSX: KXS), a global leader in end-to-end supply chain orchestration, and its solution extension partner 4flow, to transform its supply chain operations from demand to distribution. As part of its strategic growth and sustainability initiatives, Bel Group sought innovative solutions to boost operational performance, enhance collaboration and strengthen sustainability. Renowned for iconic brands like Boursin®, Babybel®, The Laughing Cow®, GoGo squeeZ®, the Group needed a robust, agile supply chain capable of withstanding any disruption as it continues to grow and diversify its product offerings. “Our foremost priority is delighting our customers with fresh, premium-quality products, delivered with precision and care,” said Xavier François, chief
Delta-Fly Pharma Inc.: Update for Development Status of the Combination Study of DFP-10917 with Venetoclax9.12.2024 12:00:00 CET | Press release
Following to the previous information on Oct. 28th. in 2024, we are excited to share our latest development status. We are pleased to announce that the data review committee (DMC) has approved the tolerability of the first three patients enrolled in the Phase I/II clinical trial of DFP-10917 in combination with Venetoclax (VEN) (NCT06382168) conducted at five US clinical sites for patients with acute myeloid leukemia (AML) who have failed/relapsed after standard VEN therapy (first-line therapy). Additionally, the bone marrow cell count in peripheral blood in all three cases was 0 (zero) within 4 (four) weeks of starting treatment, and complete remission (CR or CRi) was confirmed by subsequent bone marrow biopsy. Three more patients will be added at the current dosage regimen, and after confirmation of the tolerability, the study will move to Phase II. Complete remission has been observed in patients who have failed/relapsed after existing VEN combination therapy (first-line therapy), s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom